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ARTICLE

A pathogenic UFSP2 variant in an autosomal recessive form
of pediatric neurodevelopmental anomalies and epilepsy
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Min Ni1,2 ✉, Bushra Afroze3, Chao Xing4,5,6, Chunxiao Pan1, Yanqiu Shao6,7, Ling Cai6,8, Brandi L. Cantarel5,9, Jimin Pei10,
Nick V. Grishin10,11, Stacy Hewson12, Devon Knight13, Sonal Mahida13, Donnice Michel14, Mark Tarnopolsky15, Annapurna Poduri13,
Alexander Rotenberg13, Neal Sondheimer12 and Ralph J. DeBerardinis 1,2,4,11 ✉
PURPOSE: Neurodevelopmental disabilities are common and genetically heterogeneous. We identiﬁed a homozygous variant in
the gene encoding UFM1-speciﬁc peptidase 2 (UFSP2), which participates in the UFMylation pathway of protein modiﬁcation. UFSP2
variants are implicated in autosomal dominant skeletal dysplasias, but not neurodevelopmental disorders. Homozygosity for the
variant occurred in eight children from four South Asian families with neurodevelopmental delay and epilepsy. We describe the
clinical consequences of this variant and its effect on UFMylation.
METHODS: Exome sequencing was used to detect potentially pathogenic variants and identify shared regions of homozygosity.
Immunoblotting assessed protein expression and post-translational modiﬁcations in patient-derived ﬁbroblasts.
RESULTS: The variant (c.344T>A; p.V115E) is rare and alters a conserved residue in UFSP2. Immunoblotting in patient-derived
ﬁbroblasts revealed reduced UFSP2 abundance and increased abundance of UFMylated targets, indicating the variant may impair
de-UFMylation rather than UFMylation. Reconstituting patient-derived ﬁbroblasts with wild-type UFSP2 reduced UFMylation marks.
Analysis of UFSP2’s structure indicated that variants observed in skeletal disorders localize to the catalytic domain, whereas V115
resides in an N-terminal domain possibly involved in substrate binding.
CONCLUSION: Different UFSP2 variants cause markedly different diseases, with homozygosity for V115E causing a severe syndrome
of neurodevelopmental disability and epilepsy.
Genetics in Medicine _#####################_ ; https://doi.org/10.1038/s41436-020-01071-z

INTRODUCTION
Disorders of brain development, including those with epilepsy as a
prominent feature, are among the most genetically heterogeneous diseases of childhood. OMIM lists over 1,000 Mendelian
diseases and disease genes associated with epilepsy, and many
others with abnormal brain development and intellectual
disability. All known patterns of Mendelian inheritance have been
observed in neurodevelopmental disorders and epilepsy, as have
imprinting, mitochondrial inheritance, and polygenic effects.
Familial aggregation and twin studies have indicated that a
genetic cause underlies epilepsy in some 70% of patients.1,2 Nextgeneration sequencing has revolutionized the diagnosis of
Mendelian neurodevelopmental disorders and epilepsy, both by
enabling massively parallel analysis of known disease genes and
by uncovering genes previously unknown to be involved in
disorders of brain development.3,4
UFmylation is a system of post-translational protein modiﬁcation similar to ubiquitination in that both pathways use an E1-E2E3 cascade of reactions.5 UFMylation is initiated by cleavage of
the ubiquitin-like peptide ubiquitin-fold modiﬁer-1 (UFM1),
exposing a glycine residue on UFM1 and rendering it competent
for conjugation. This cleavage step is followed by UFM1
adenylation and conjugation to the E1 component, Ubiquitin-

like modiﬁer activating enzyme 5 (UBA5).6,7 UFM1 is then
transferred to the E2 conjugating enzyme UFM1-conjugase 1
(UFC1).8 UFM1-conjugated UFC1 and a UFMylation target
protein are recruited to the endoplasmic reticulum (ER) membrane
by the noncatalytic RING-type E3 component UFM1-ligase 1
(UFL1).9 Subsequent, incompletely understood steps lead to
mono- or poly-UFMylation of the target protein at the cytosolic
face of the ER, followed by release of the UFMylated target into
the cytosol.
UFSP1 and UFSP2 encode cysteine proteases that cleave UFM1
in the initial step of UFMylation, with UFSP1 performing this
cleavage much more efﬁciently than UFSP2 in vitro.6 In addition to
their role in producing mature UFM1, both proteases also possess
the ability to release UFM1 from UFMylated proteins in a process
termed de-UFMylation.6,10 The relative importance of UFMylation
and de-UFMylation are unknown, and the extent to which UFSP1
and UFSP2 can compensate for each other in vivo has been
incompletely explored. Core components of the UFMylation
system are conserved throughout metazoans, and loss of
components of the UFMylation cycle results in defects in
embryogenesis, hematopoiesis, and cellular differentiation in
model systems.5 However, the precise mechanisms by which
UFMylation alters proteostasis are unknown.
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In humans, variants in UFSP2’s catalytic domain have been
reported in autosomal dominant disorders of the skeletal system,
including spondyloepimetaphyseal dysplasia, Di Rocco type
(OMIM 617974) and Beukes hip dysplasia in a large Afrikaner
family from South Africa (OMIM 142669).11–13 These conditions are
not reported to cause neurological dysfunction or epilepsy. We
report a rare homozygous missense variant in a different UFSP2
domain in four South Asian families with a severe neurological
disorder involving intellectual disability, epilepsy, microcephaly,
abnormal eye movements, and poor growth.
MATERIALS AND METHODS
Patient samples
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For family 1, whole blood was collected from patients 1–3 and their
parents, processed at University of Texas Southwestern Medical Center
(UTSW) and subjected to exome sequencing (ES) as described below.
Patients 4–8 were analyzed by ES in clinical laboratories as a part of their
diagnostic workup at Boston Children’s Hospital (patients 4 and 5), The
Hospital for Sick Children in Toronto (patient 6), and McMaster University
(patients 7 and 8). Punch biopsies of the skin for ﬁbroblast culture were
obtained from patients 1–3 using standard clinical methods. DNA or buccal
swab samples were collected from the unaffected siblings in family 1 (IV.2
in Fig. 1a) and family 3 (III.4 in Fig. 1d), respectively.

Exome sequencing and genomic analysis
Genomic DNAs of the patients and parents from families 1 and 3 were
subjected to library preparation using the SureSelect V5 kit (Agilent)
following the manufacturer’s instructions. Sequencing was performed on a
NovaSeq6000 with 150 bases of paired-end reads to target 200× of raw
depth (Psomagen). BWA-MEM was used to align sequence reads to
reference genome GRCh37. Post-BAM processing was performed using
BWAKit, Samtools 1.4, Sambamba, and GATK 3.7.14,15 Variants were
detected using GATK 3.7, Platypus,16 Samtools version 1.4, and FreeBayes
version 0.9.7 (unpublished data). A union VCF ﬁle was created with the
results from each individual caller for subsequent ﬁltering. The effects of
single-nucleotide polymorphisms (SNPs) and indels were predicted using
snpEff.17 Population frequency was annotated based on gnomAD.18 The
blood or DNA samples from the patients and parents in families 2, 3, and 4
were submitted to GeneDx for their CLIA-compliant exome sequencing
service.
Because of the consanguinity in family 1, the disorder was suspected to
be inherited in an autosomal recessive fashion. We therefore ﬁltered for
rare missense, nonsense, splicing, or frameshift variants that were
homozygous in the patients and heterozygous in the parents, and have
a minor allele frequency (MAF) less than 0.01 in gnomAD (v2.1.1; http://
gnomad.broadinstitute.org/). Considering the possibility of shared ancestry
among the families, ES data from families 1 and 3 were also used to
identify runs of homozygosity (ROH) shared by the four affected patients
(P1, P2, P3, P6) but not by their unaffected parents using BCFtools/RoH.19

Sanger genotyping
The UFSP2 variant was conﬁrmed by Sanger sequencing in the three
patients and four parents from family 1, and unaffected siblings in families
1 and 3 with genotypes indicated on the pedigrees in Fig. 1. A 415-bp
region covering the V115 codon was polymerase chain reaction (PCR)
ampliﬁed (forward primer: 5’-GGCTGGTCTGAGGGTAGTGA-3’; reverse
primer: 5’-TCATTCAAATGTGGCAGTGG-3’). The genotypes were then
determined by Sanger sequencing (GENEWIZ).

Immunoblotting
Whole cell or tissue lysates were extracted using ice-cold TNE buffer
(10 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid [EDTA], and protease inhibitors)10 followed by
three freeze–thaw cycles. The protein supernatants were quantiﬁed using
the BCA protein assay (Pierce, 23227). Proteins were separated on 4–20%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
gels (Bio-Rad), transferred to PVDF membranes, and probed with primary
antibodies against the indicted proteins, including anti-UFSP2 (Proteintech,
16999-1-AP), anti-UFM1 (Abcam, ab109305), anti-DDRGK1 (Proteintech,
21445-1-AP), anti-TRIP4 (Proteintech, 12324-1-AP), anti-RPL26 (Cell

Signaling, 2065), anti-BiP (Cell Signaling, 3177), anti-XBP1s (Cell Signaling,
12782), anti-GAPDH (Cell Signaling, 8884), anti-UFSP1 (Santa Cruz
Biotechnology, sc-398577) and anti-Calnexin (Enzo Life Sciences, ADISPA-860-F) antibodies. Immunoreactive proteins were visualized
by enhanced chemiluminescence (Pierce, 32106). Signal intensities for
the anti-UFM1 were quantiﬁed using ImageJ. In Fig. 3b, the error bars
are the SD for the same three control and three patient samples on the
blot in Fig. 3a, and a two-tailed unpaired t-test was used to compare the
groups.

Quantitative real-time PCR
Total RNA was isolated from 6×105 ﬁbroblasts using the RNeasy minikit
(Qiagen) according to the manufacturer’s protocol. 1 μg of RNA was used
for complementary DNA (cDNA) synthesis using with the iScript™ cDNA
Synthesis Kit (Bio-Rad). Quantitative real-time (RT-PCR) was performed
using the SYBR Green mix (Bio-Rad). The UFSP2 cDNA was PCR ampliﬁed
using forward primer 5’-GTTATGATCGGGGGAGGAGT-3’ and reverse primer
5’-CAGGTCTTCAGCACCGGTAT-3’. In Fig. 3c, the data are the average and
SD for three technical replicates from each cell line. Data between the
controls and patients were compared by unpaired t-tests and found not to
differ signiﬁcantly.

Molecular cloning, lentiviral production, and transduction
Wild-type and V115E-mutant open reading frames (ORFs) of human UFSP2
were PCR ampliﬁed from the cDNA pool of HEK293T cells or the ﬁbroblasts
of patient P1, respectively. We used the following primers for PCR
ampliﬁcation: 5’-AGATCTGCCGCCGCGATGGTGATTTCAGAAAGTATGGAT-3’
(forward) and 5’-GCGGCCGCGTACGCGAATCATATTTGGTCGCTGAGGA-3’
(reverse). The fragments were puriﬁed and cloned into pLenti-EF1a-CMyc-DDK-IRES-Puro (OriGene) using the In-Fusion HD Cloning Kit following
the manufacturer’s instructions (Takara Bio). The positive clones were
conﬁrmed by Sanger sequencing (GENEWIZ). Lentivirus was produced by
transfecting HEK293T cells using lipofectamine 3000 reagent (Thermo
Fisher Scientiﬁc). Viral supernatants were harvested at 48 hours and 72
hours, ﬁltered through a 0.45-μm ﬁlter, and concentrated using PEG-it Virus
Precipitation Solution (System Biosciences). For transduction, the lentiviral
pellets were suspended in culture medium and added to ﬁbroblasts at
70–80% conﬂuency in 6-well plates. After 48 hours of transduction, the
ﬁbroblasts were selected under puromycin for one week for stable
expression of wild-type or mutant UFSP2.

RESULTS
Homozygous UFSP2 missense variant in a severe, early-onset
neurological disorder
Clinical features of the patients are summarized in Table 1.
Patients 1–3 are from a consanguineous family (family 1) in
Pakistan whose four-generation pedigree is shown in Fig. 1a.
Patients 1 (IV.1) and 2 (IV.4) were born to ﬁrst-cousin parents, and
patient 3 (IV.6) was born to a different set of ﬁrst-cousin parents
within the same kindred. Two of these children were at or below
the 5th percentile for weight at birth, and all three have displayed
poor postnatal weight gain. Two patients are microcephalic. All
three had early-onset, generalized epilepsy and nonparalytic
convergent strabismus. All patients have marked developmental
impairments. At age 3, patient 3 (IV.6) can toe-walk with
assistance, smile, engage in simple nonverbal communications
(e.g., tapping her head), and feed herself ﬁnger foods. The other
two patients are hypotonic with minimal head control, no walking,
and essentially no communication beyond occasional vocalizations. A brain magnetic resonance image (MRI) was performed in
patient 1 (IV.1) and revealed bilateral thinning of the deep
periventricular white matter and cerebellar hypoplasia.
ES was performed in the three patients and their parents in
family 1. Only one missense variant in UFSP2 (NC_000004:
g.186337011A>T; NM_018359: c.344T>A; NP_060829: p.V115E;
rs142500730) passed the ﬁltering criteria. All three patients were
homozygous and their unaffected parents were heterozygous. The
ES results were conﬁrmed by Sanger sequencing, which also
demonstrated that the unaffected sibling IV.2 is homozygous for
Genetics in Medicine _#####################_
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Fig. 1 Pedigrees of four unrelated families with affected children carrying the homozygous UFSP2 p.V115E variant. (a) Pedigree showing
the relationship of the three affected patients indicated as P1, P2, and P3 from a consanguineous Pakistani kindred (family 1). Genotype
annotations show the nucleotide as T for wild-type and A for variant. (b) Chromatogram of UFSP2 sequences conﬁrming parental
heterozygosity (III.3, III.4, III.5, and III.8) for c.344T>A, homozygosity for the variant in the three patients (IV.1, IV.4, and IV.6) and homozygous
wild-type in the unaffected sister (IV.2). (c) Family of patients P4 and P5 (family 2). Three individuals (II.6, II.7, and III.1) who died with unknown
neurological disorders are shaded in light gray. (d) Family of patient P6 (family 3). AW alive and well. (e) Family of patients P7 and P8 (family 4).
The female sibling III.4 had a clinically similar disorder and died at 8 years of age. DNA was not available for UFSP2 sequencing.
(f) Representative magnetic resonance images (MRIs), including P5, cerebellar volume loss (left) and cortical volume loss (right); P6, mild
cerebellar volume loss (left) and mild hypomyelination (right); P7, moderate prominence of cortical cerebrospinal ﬂuid (CSF) space. Highresolution electronic images were not available for P1–P3.

the wild-type sequence (Fig. 1b). We submitted this variant to
ClinVar with the accession number of SCV001338803.
Depositing this variant together with phenotypic information
into GeneMatcher (https://genematcher.org) led to the identiﬁcation of ﬁve additional homozygotes from Pakistan and Afghanistan (Table 1, Fig. 1c–e). In all these patients, the variant was
detected by clinical ES and all parents are asymptomatic
heterozygotes. Patients 4 and 5 were born to double ﬁrst-cousin
Genetics in Medicine _#####################_

parents from Pakistan. Both are nonambulatory and nonverbal,
with dystonic movements and epilepsy appearing within the ﬁrst
few months of life. At age 1.5 years, patient 4’s brain MRI displayed
nonspeciﬁc T2 signal hyperintensity in the periventricular white
matter and globi pallidi, right sided mesial temporal sclerosis,
thinned corpus callosum, underopercularization of the Sylvian
ﬁssures, small optic nerves, and delayed myelination. At age 2,
patient 5’s MRI revealed volume loss in the cortex, cerebellum, and
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Fig. 2 Runs of homozygosity analysis in families 1 and 3. (a) Chromosomal distribution of homozygous regions in patients P1, P2, P3, and
P6. The displayed regions are larger than 1 Mb and are homozygous in the patients but not the parents. The sole homozygous region shared
by all four patients is indicated by the red frame on chromosome 4. (b) Schematic of homozygous segments on chromosome 4q in families 1
and 3. For each individual, the top line displays markers with homozygous genotypes and the bottom line displays markers with heterozygous
genotypes. The homozygous regions are highlighted in color blocks: red for regions common to more than one individual, gray for regions
unique to one individual. The UFSP2 locus is indicated.

frontal lobe (Fig. 1f). Three other individuals in this family were
reported to have had neurological diseases of unknown cause, but
additional details were unavailable.
Patient 6 is a girl born to parents from Afghanistan with no
reported consanguinity. She has poor weight gain, microcephaly,
esotropia, and infantile spasms with onset at age 3 months
(Table 1). At age 2, the child can bring her hands to her mouth but
cannot reach for or hold objects. She is unable to roll, sit, or stand
and has no speech. A brain MRI at age 2 revealed delayed
myelination and mild cerebellar volume loss (Fig. 1f).
Patients 7 and 8 are sibling girls in a family from Afghanistan
with no reported consanguinity. These two patients had infantile
spasms before 4 months, hypotonia, and severe intellectual
impairment (Table 1). The older sibling (patient 8, III.7 on the
pedigree) can move her arms and legs independently but cannot
sit or crawl. The younger (patient 7, III.8) is not able to roll over.
They also had an older sister (III.4) who died at age 8 with a similar
disorder and was never able to crawl. In patient 7, a brain MRI at
age 2 months revealed mild-to-moderate prominence of the
cortical cerebrospinal ﬂuid (CSF) space but age-appropriate
myelination and no other abnormalities (Fig. 1f). MR spectroscopy
in this patient revealed normal lactate but some voxels with low
N-acetylaspartate to choline and N-acetylaspartate to creatine
ratios.
This UFSP2 variant is rare, although its allele frequency is higher
in South Asians (MAF = 0.00089) compared with non-Finnish
Europeans (MAF = 0.000035) and other populations in the
gnomAD database (v2.1.1). Given that many families in Pakistan
and Afghanistan belong to the Pathan ethnic group, homozygosity for this variant in our subjects might suggest shared ancestry
and enhanced autosomal homozygosity among the affected
families. We performed ROH analysis to evaluate the genomewide homozygosity in patients and parents of families 1 and 3,
Genetics in Medicine _#####################_

where complete ES data were readily available. Comparing
homozygous genomic regions identiﬁed in each patient (P1, 2,
3, and 6) but not in the parents revealed two adjacent stretches of
homozygosity measuring 2.4 and 1.7 Mb on chromosome 4q. The
UFSP2 locus is within the 2.4 Mb region (Fig. 2a,b and Table S1).
None of the parents are homozygous at the UFSP2 locus, although
the mother of patient 6 (II.5 in Fig. 1d) does contain a small region
of homozygosity within the 1.7 Mb block (Fig. 2b). Clinical ES data
were not readily available for families 2 and 4, so we do not know
whether the patients in these families share the same haplotype
as those in families 1 and 3.
The cosegregation of UFSP2 p.V115E with the disease in
multiple families constitutes strong evidence for its pathogenicity.
The probability (N) that genotype–phenotype cosegregation
occurred by chance is (1/4)3 × (3/4)2 ≈ 0.009, where the ﬁrst
factor corresponds to the three affected sibpairs in families 1, 2,
and 4, and the second factor corresponds to the unaffected
siblings in families 1 and 3. This is lower than the recommended
criterion of N ≤ 1/16 (0.06) for strong evidence of pathogenicity.20
Note that in family 1 we took a conservative approach by
assuming that the most recent common ancestor of the
rs142500730[T] allele was before generation I, and therefore did
not include patient 3 in the calculation. With this evidence for
pathogenicity, we proceeded to functional analysis of the variant.
Functional analysis of UFSP2 and UFMylation in ﬁbroblasts from
affected patients
Skin biopsies were performed in patients 1–3 to establish
ﬁbroblast cultures. Immunoblotting of proteins extracted from
these cell lines revealed markedly reduced UFSP2 levels relative to
cells derived from healthy subjects (Fig. 3a). UFSP2 messenger RNA
(mRNA) levels assessed by quantitative RT-PCR revealed no
differences among the cultures, indicating that the effect of the
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Fig. 3 UFSP2 expression and UFMylation marks in patient and control ﬁbroblasts. (a) Immunoblot analysis of primary human ﬁbroblasts
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proteins in P1 and P3 ﬁbroblasts ectopically expressing wild-type (WT) or V115E variant of UFSP2.

variant was likely not mediated by changes in RNA stability
(Fig. 3c). An antibody against UFM1 revealed that the patients’
cells contained enhanced levels of several UFM1-conjugated
proteins, including DDRGK1, TRIP4 and RPL26, despite no
substantial increases in the total abundance of these proteins
(Fig. 3a, b). Ectopic expression of wild-type UFSP2 but not the
mutant normalized the levels of UFMylated proteins in patient
ﬁbroblasts (Fig. 3d). The ectopically expressed mutant was difﬁcult
to detect by immunoblotting, consistent with the V115E variant
causing UFSP2 destabilization.
Mammalian UFMylation is carried out by a multiprotein
complex predominantly located at the cytosolic side of the ER
membrane, and the pathway is involved in vesicular trafﬁcking
and ER homeostasis.21–23 Disruption of UFMylation pathway
induces ER stress and activates the unfolded protein response in
mouse hematopoietic stem cells24,25 and cardiomyocytes.26
However, no activation of ER stress was detected in the three
UFSP2-mutant ﬁbroblast lines as assessed by immunoblotting for
the ER stress markers GRP78 and spliced XBP1 (Fig. 3a).
UFSP2 expression and structural aspects of disease-causing
variants
Although disease-causing UFSP2 variants have been reported in
humans, these diseases involve skeletal anomalies rather than
neurological dysfunction. Patients with autosomal dominant
Beukes hip dysplasia have a Y290H variant in UFSP2.12 Spondyloepimetaphyseal dysplasia, Di Rocco type (SEMDDR) occurred in
an Italian family with a D426A variant in UFSP211 and a Chinese
patient with a H428R variant.13 None of the reported patients with
these diseases had neurological impairments or seizures. Y290,
D426, and H428 are located in UFSP2’s C-terminal C78 peptidase
domain required for its catalytic activity (Fig. 4a), whereas V115 is
within the N-terminal domain that interacts with DDRGK1, an ERlocalized UFMylation target.9 V115 is highly conserved across
species, including all vertebrates studied (Fig. 4b). Threedimensional structural analysis of the mouse homolog (Protein

Data Bank [PDB]: 3OQC) revealed that the N-terminal region of
Ufsp2 consists of mixed α-helices and β-strands.27 The homologous
Val in mouse Ufsp2 (V107) is located at the β3 strand and in the
core of the protein–protein interacting domain (Fig. 4c). Mutating
Val to Glu introduces a larger, less hydrophobic and negatively
charged residue into the β-sheet structure, a change predicted to
impair the local hydrophobic interactions. Human UFSP2 Y290,
D426, and H428 are equivalent to mouse Ufsp2 Y282, D418, and
H420 (Fig. 4c), which contribute to the catalytic core in the active
site of the mouse protein.27 Mutating Y282 to His inactivated
Ufsp2’s catalytic activity.27 These data suggest that variants
observed in human skeletal dysplasias impact UFSP2’s catalytic
activity, but the V115E variant in patients with neurological
disorders may have other effects including reduced protein
stability and possibly reduced interaction with UFMylated targets.
To obtain insights into UFSP2’s relevance to neurological
disease, we examined the expression of UFSP2 and several
UFMylation targets across mouse and human tissues. According
to the Genotype–Tissue Expression (GTEx) database, UFSP2 and
DDRGK1 mRNAs are expressed in multiple regions of the human
brain (Fig. 4d). Immunoblotting conﬁrmed expression of UFSP2
and DDRGK1, as well as the UFMylation target TRIP4, in human
brain (Fig. 4e). Ufsp2, Ddrgk1, Trip4, and the UFMylation target
Rpl26 were also observed in the mouse brain, although Ddrgk1
was much less abundant in the brain than in mouse pancreas
and liver.
DISCUSSION
Pediatric neurodevelopmental syndromes involving epilepsy are
genetically heterogeneous. Although ES increasingly identiﬁes
genomic variants in patients with these diseases, establishing the
pathogenicity of such variants is challenging. Using guidelines
from the American College of Medical Genetics and Genomics and
Association for Molecular Pathology, together with the additional
information provided by cosegregation analysis,20,28 the UFSP2
c.344T>A (p.V115E) variant qualiﬁes as pathogenic based on the
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following criteria: (1) cosegregation probability less than 1/16 in
an analysis involving multiple families, (2) functional studies
supporting a damaging effect on the gene product, (3) extremely
low frequency in gnomAD (overall MAF = 0.00013), and (4)
detected in trans as a recessive allele. Criteria 1 and 2 are
considered strong evidence for pathogenicity, while criteria 3 and
4 are considered moderately supportive of pathogenicity;
together these data meet the threshold for pathogenicity. The
structural and evolutionary analysis of UFSP2, its expression in the
relevant tissues, and the lack of other shared, potentially diseasecausing alleles among the families in the study, further support
the variant’s pathogenicity in the neurologic disease observed in
our patients.
Ample evidence from human genetics indicates that UFMylation is important in brain development, as several components of
the pathway are mutated in autosomal recessive diseases
affecting the central nervous system. Similar to the patients
described here, UFM1 variants cause a disorder of severe
intellectual disability, intractable epilepsy, microcephaly, and poor
growth (leukodystrophy, hypomyelinating, 14, HLD14, OMIM
617899). This disease has been described in families of Roma
and Sudanese descent.29,30 UBA5 variants cause a subtype of early
infantile epileptic encephalopathy, with ﬁbroblasts from the
Genetics in Medicine _#####################_

affected individuals suggesting dysfunctional E1-like activity in
the mutants (EIEE44, OMIM 617132).31,32 UBA5 variants have also
been reported in individuals with an autosomal recessive form of
spinocerebellar ataxia (SCAR24, OMIM 617133).33 Variants in UFC1,
which encodes the E2 component, cause an autosomal recessive
neurodevelopmental disorder with spasticity and poor growth
(NEDSG, OMIM 618076).30,34
Our study connects UFSP2 to a phenotype with overlapping
features, providing further evidence for the importance of
UFMylation in human brain development. We demonstrate that
UFSP2 and at least one UFMylated protein, DDRGK1, are expressed
in the human brain. Previously reported defects in UFM1 and in
the E1 and E2 components of the pathway were associated
with decreased function of the UFMylation cascade,30–32 suggesting that the pathology involves an interruption in UFMylationdependent mechanisms of target protein function. Reduced
UFSP2 expression in ﬁbroblasts indicates a loss of function
effect for the V115E variant, and we anticipated that
these cells would also display reduced UFMylation. The
increased levels of UFMylated targets in these cells suggest
that the variant more prominently affects de-UFMylation
rather than UFMylation. Reconstituting ﬁbroblasts with wildtype UFSP2 reduced UFMylation marks, also indicating defective
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de-UFMylation in the patients’ cells. We do not know how the
variant affects UFMylation in the brain, but we speculate that
UFSP1 or other enzymes compensate for pro-UFM1 cleavage in
some tissues, thereby allowing UFMylation to occur even in
the context of hypomorphic UFSP2 variants. The functions of
UFSP1 and UFSP2 are at least partially redundant, as in vitro
assays have demonstrated that both UFSP1 and UFSP2 can
cleave pro-UFM1 and release UFM1 from UFMylated proteins.6
However, while these proteins share sequence similarity in their
C-terminal catalytic domains, UFSP2 is more than twice as large.
The N-terminal domain that contains V115 and appears to
promote associations with UFMylated proteins is unique to UFSP2.
This may explain how variants in this region result in excess
UFMylation of at least some targets. Our data also suggest that
V115 is required for protein stability, perhaps through substrate
binding, because homozygosity for V115E results in reduced
UFSP2 abundance.
Along these lines, a curious aspect of the UFSP2 variant
described here is that the V115E substitution results in central
nervous system dysfunction but no obvious skeletal anomalies,
while other UFSP2 variants result in autosomal dominant skeletal
dysplasias but no seizures or defects in intellectual development.11–13 These previous reports, along with the observation of
DDRGK1 variants in an autosomal recessive skeletal disorder
(spondyloepimetaphyseal dysplasia, Shohat type, OMIM 616177)
provide convincing evidence that UFMylation is required in the
human skeletal system. These UFSP2 variants are localized within
the peptidase domain, unlike the V115E variant described here.
The variant in Beukes hip dysplasia reduces UFSP2’s in vitro
catalytic activity, although its effects on the levels of UFMylated
proteins in cells is unknown.12 Understanding the pathophysiology of these UFSP2-related diseases will require a more
comprehensive assessment of how each variant alters the
UFMylated proteome in relevant tissues, and how these changes
impact the function of UFMylated proteins.
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